跳至主要内容
临床试验/NCT00927043
NCT00927043已完成不适用

Prospective, Multicenter, Epidemiological Study To Determine The Clinical, Molecular And Genetic Factors Associated To The Prognosis Of Patients With Advanced Renal Cell Carcinoma

Pfizer1 个研究点 分布在 1 个国家目标入组 145 人开始时间: 2009年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Pfizer
入组人数
145
试验地点
1
主要终点
Progression-free survival

研究概览

简要总结

This is an epidemiological, prospective, multicenter study designed to identify the pre-treatment clinical, molecular and genetic prognostic factors associated with progression free survival in patients naïve to renal cell carcinoma (RCC) treatment.

详细描述

invitation to volunteer

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Treatment naïve patients with proven advanced RCC will be evaluated. (Except surgery or radiotherapy)
  • =18 years, any gender.
  • Patients with advanced Renal Cell Carcinoma and treatment naïve.

排除标准

  • Patients who have already initiated any kind of specific therapy for the treatment of RCC.
  • Patients with other neoplasias different from RCC (current or past).

结局指标

主要结局

Progression-free survival

时间窗: 12 months

次要结局

  • Response rate.(12 months)
  • Overall survival.(12 months)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验